The Outlook for BRAF Inhibitors in Melanoma

A survey shows doctors are looking to upgrade their EHR systems to better support value-based care by collecting patient outcome data and integrating with AI.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).

In a Peers & Perspectives in Oncology feature article, we focus on the importance of the transition-of-care process for patients with cancer as they move from the inpatient to outpatient setting, as well as between lines of therapy with comments from Marc J. Braunstein, MD, PhD, and Michael Shusterman, MD.